School of Medicine
Showing 1-3 of 3 Results
-
Arash Keshavarzi
Postdoctoral Scholar, Cardiovascular Medicine
BioArash Keshavarzi, PhD, has a background in Molecular Biology and AI drug discovery, with experience bridging AI and biotechnology. He used to be the CSO of Nucleus Genomics, a company that has raised over $30 million in funding from prominent investors including Founders Fund. He is the Co-founder of Lumos Bio, a UCSF spin-off focused on pioneering RNA-targeting cancer therapeutics, and also a co-founder of Entelligent.ai, driving innovation in AI driven intelligence. Additionally, Arash is actively involved in venture capital and investment as an Investment Fellow at Mubadala Capital, where he builds investment thesis, sources deals, and helps both biotech and AI teams. His career uniquely blends deep scientific expertise, entrepreneurial acumen, and strategic investment insights.
He has published over 10 academic papers in AI Therapeutics fields
He has published two book chapter in AI medicine
He has two patents in AI for small molecule drug discovery, one approved, one pending -
Pik Fang Kho
Postdoctoral Scholar, Cardiovascular Medicine
BioI obtained my PhD in genetic epidemiology at Queensland University of Technology (Australia), where my research was focused on using genetic and genomic approaches to identify risk factors for endometrial cancer. During my graduate studies, I gained experience in large-scale genetic association studies and leveraging the correlation between diseases in genetic studies to identify novel genetic variants associated with endometrial cancer. I also developed expertise in various statistical genetic approaches in multi-omics data, including fine-mapping and colocalization analyses, to prioritize candidate causal variants and genes. I also gained extensive experience in genetic causal inference analysis to infer causality between risk factors and health outcomes.
My research focus since moving to Stanford has been the identification of genetic and non-genetic determinants of cardiometabolic diseases. I am currently involved in projects including large-scale genetic association studies, multi-trait analysis with correlated traits, development and validation of polygenic risk scores, integrative analyses with multi-omics data, as well as Mendelian randomization analyses to advance our understanding of the genetic and environmental factors that contribute to cardiometabolic diseases.
